PUBCHEM ID | 10465 |
Molecular Weight (g/mol) | 270.451 |
Molecular Formula | C17H34O2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 15 |
IUPAC Name | heptadecanoic acid |
Canonical SMILES | CCCCCCCCCCCCCCCCC(=O)O |
PUBCHEM IUPAC INCHIKEY | KEMQGTRYUADPNZ-UHFFFAOYSA-N |
Solubility Level | 2 |
Vapour Pressure | -6.235 |
XLOGP3 AA | |
CACTVS TPSA | 37.3 |
BBB Level | 4 |
Absorption Level | 2 |
EXT PPB#Prediction | 1 |
AlogP98 | 6.849 |
EXT CYP2D6#Prediction | 0 |
Mouse Female FDA | Non-Carcinogen |
Mouse Male FDA | Single-Carcinogen |
Rat Female FDA | Non-Carcinogen |
Rat Male FDA | Non-Carcinogen |
Ames Prediction | Non-Mutagen |
Developmental / Reproductive Toxicity | Non-Toxic |
Rat Oral LD50 | 8.97564 g/kg_body_weight |
Ocular Irritancy | None |
Hepatotoxic#Prediction | 0 |
Effected Human Genes |
Aerobic Biodegradability Prediction | Degradable |
Physical hazards | not classified |
Health hazards | Moderate |
Environmental hazards | not classified |
Serial No. | Cas No | Gene Symbol | Organism | Interaction | Interaction Actions | PubMed Id |
---|---|---|---|---|---|---|
1 | 506-12-7 | INS | Mus musculus | [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased abundance of margaric acid analog | affects^cotreatment|increases^abundance | 26820058 |
Serial No. | Activity Name | Details | References (PubMed) | Other details EPA (U.S) | Clinical Trials (U.S. NIH) |
---|---|---|---|---|---|
1 | 506-12-7 | Heptadecanoic |